A variety of malignancies, particularly colorectal cancer with significant microsatellite instability, have shown improved clinical outcomes when treated with inhibitors targeting CD274 (PD-L1) or PDCD1 (PD-1) proteins [41]. This evidence concerns the gene PDCD1 and colorectal cancer.